FrankHAChaoMTremlettH, et al. Comorbidities and their association with outcomes in the multiple sclerosis population: A rapid review. Mult Scler Relat Disord2024; 92: 105943.
2.
JakimovskiDTopolskiMGenoveseAV, et al. Vascular aspects of multiple sclerosis: Emphasis on perfusion and cardiovascular comorbidities. Expert Rev Neurother2019; 19(5): 445–458.
3.
MarrieRAFiskJDFitzgeraldK, et al. Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances. Front Immunol2023; 14: 1197195.
4.
JakimovskiDGandhiSPaunkoskiI, et al. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: A 5-year longitudinal study. Eur J Neurol2019; 26(1): 87.e–87.e8.
5.
LoreficeLFenuGPitzalisR, et al. Autoimmune comorbidities in multiple sclerosis: What is the influence on brain volumes? A case-control MRI study. J Neurol2018; 265(5): 1096–1101.
6.
LoreficeLFrauJCogheG, et al. Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case-control MRI study. Mult Scler Relat Disord2019; 27: 74–78.
7.
ChatawayJSchuererNAlsanousiA, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet2014; 383: 2213–2221.
8.
SternbergZLeungCSternbergD, et al. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther2014; 32(2): 33–39.
9.
AyrignacXLarochelleCKeezerM, et al. Frailty in ageing persons with multiple sclerosis. Mult Scler2021; 27(4): 613–620.
10.
JakimovskiDWeinstock-GuttmanBGandhiS, et al. Dietary and lifestyle factors in multiple sclerosis progression: Results from a 5-year longitudinal MRI study. J Neurol2019; 266(4): 866–875.
